AMGN vs. SNY: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and SNY, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AMGN’s market capitalization stands at 160.37 billion USD, while SNY’s is 117.68 billion USD, indicating their market valuations are broadly comparable.
With betas of 0.50 for AMGN and 0.41 for SNY, both stocks show similar sensitivity to overall market movements.
SNY is an American Depositary Receipt (ADR), allowing U.S. investors direct exposure to its non-U.S. operations. AMGN, on the other hand, is a domestic entity.
| Symbol | AMGN | SNY |
|---|---|---|
| Company Name | Amgen Inc. | Sanofi |
| Country | US | FR |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| CEO | Robert A. Bradway | Paul Hudson |
| Price | 298.24 USD | 48.3 USD |
| Market Cap | 160.37 billion USD | 117.68 billion USD |
| Beta | 0.50 | 0.41 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 17, 1983 | July 1, 2002 |
| ADR | No | Yes |
Historical Performance
Performance data is currently unavailable.
Profitability
Return on Equity
AMGN
92.94%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
In the upper quartile for the Drug Manufacturers - General industry, AMGN’s Return on Equity of 92.94% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
SNY
8.48%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
SNY’s Return on Equity of 8.48% is in the lower quartile for the Drug Manufacturers - General industry. This indicates a less efficient generation of profit from its equity base when compared to its competitors.
Return on Invested Capital
AMGN
9.53%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AMGN’s Return on Invested Capital of 9.53% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
SNY
6.04%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
SNY’s Return on Invested Capital of 6.04% is in the lower quartile for the Drug Manufacturers - General industry. This indicates a less efficient conversion of invested capital into profit compared to most of its competitors.
Net Profit Margin
AMGN
17.39%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AMGN’s Net Profit Margin of 17.39% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
SNY
14.39%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
SNY’s Net Profit Margin of 14.39% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
Operating Profit Margin
AMGN
21.82%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AMGN’s Operating Profit Margin of 21.82% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
SNY
18.55%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
SNY’s Operating Profit Margin of 18.55% is in the lower quartile for the Drug Manufacturers - General industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.
Profitability at a Glance
| Symbol | AMGN | SNY |
|---|---|---|
| Return on Equity (TTM) | 92.94% | 8.48% |
| Return on Assets (TTM) | 6.64% | 4.78% |
| Return on Invested Capital (TTM) | 9.53% | 6.04% |
| Net Profit Margin (TTM) | 17.39% | 14.39% |
| Operating Profit Margin (TTM) | 21.82% | 18.55% |
| Gross Profit Margin (TTM) | 63.00% | 71.13% |
Financial Strength
Current Ratio
AMGN
1.17
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AMGN’s Current Ratio of 1.17 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
SNY
1.37
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
SNY’s Current Ratio of 1.37 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio
AMGN
9.24
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
With a Debt-to-Equity Ratio of 9.24, AMGN operates with exceptionally high leverage compared to the Drug Manufacturers - General industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
SNY
0.28
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
Falling into the lower quartile for the Drug Manufacturers - General industry, SNY’s Debt-to-Equity Ratio of 0.28 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio
AMGN
3.19
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
In the lower quartile for the Drug Manufacturers - General industry, AMGN’s Interest Coverage Ratio of 3.19 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
SNY
13.25
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
SNY’s Interest Coverage Ratio of 13.25 is positioned comfortably within the norm for the Drug Manufacturers - General industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | AMGN | SNY |
|---|---|---|
| Current Ratio (TTM) | 1.17 | 1.37 |
| Quick Ratio (TTM) | 0.88 | 0.69 |
| Debt-to-Equity Ratio (TTM) | 9.24 | 0.28 |
| Debt-to-Asset Ratio (TTM) | 0.64 | 0.16 |
| Net Debt-to-EBITDA Ratio (TTM) | 3.92 | 1.29 |
| Interest Coverage Ratio (TTM) | 3.19 | 13.25 |
Growth
Financial growth data is currently unavailable for comparison.
Dividend
Dividend Yield
AMGN
3.10%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.10% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.
SNY
4.71%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
With a Dividend Yield of 4.71%, SNY offers a more attractive income stream than most of its peers in the Drug Manufacturers - General industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
AMGN
82.64%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AMGN’s Dividend Payout Ratio of 82.64% is in the upper quartile for the Drug Manufacturers - General industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
SNY
74.68%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
SNY’s Dividend Payout Ratio of 74.68% is within the typical range for the Drug Manufacturers - General industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AMGN | SNY |
|---|---|---|
| Dividend Yield (TTM) | 3.10% | 4.71% |
| Dividend Payout Ratio (TTM) | 82.64% | 74.68% |
Valuation
Price-to-Earnings Ratio
AMGN
27.04
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
A P/E Ratio of 27.04 places AMGN in the upper quartile for the Drug Manufacturers - General industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
SNY
16.32
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
In the lower quartile for the Drug Manufacturers - General industry, SNY’s P/E Ratio of 16.32 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
AMGN
7.57
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AMGN’s Forward PEG Ratio of 7.57 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
SNY
1.76
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
In the lower quartile for the Drug Manufacturers - General industry, SNY’s Forward PEG Ratio of 1.76 is a positive indicator. It suggests that the stock may be attractively valued relative to its expected earnings growth.
Price-to-Sales Ratio
AMGN
4.70
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AMGN’s P/S Ratio of 4.70 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
SNY
2.32
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
SNY’s P/S Ratio of 2.32 aligns with the market consensus for the Drug Manufacturers - General industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
AMGN
25.85
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
SNY
1.39
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
Valuation at a Glance
| Symbol | AMGN | SNY |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.04 | 16.32 |
| Forward PEG Ratio (TTM) | 7.57 | 1.76 |
| Price-to-Sales Ratio (P/S, TTM) | 4.70 | 2.32 |
| Price-to-Book Ratio (P/B, TTM) | 25.85 | 1.39 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 14.69 | 63.86 |
| EV-to-EBITDA (TTM) | 16.88 | 11.35 |
| EV-to-Sales (TTM) | 6.12 | 2.62 |